Could a week off GLP-1 drugs make endoscopies safer and more effective?

NCT ID NCT07736911

Recruiting now Disease control Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial asks whether pausing GLP-1 receptor agonists (like semaglutide or tirzepatide) for one week before an upper endoscopy leads to a cleaner stomach and fewer repeat procedures. About 140 adults who take these drugs and are scheduled for an endoscopy will be randomly assigned to either stop their medication for a week or continue as usual. The goal is to see if a simple drug holiday can improve the quality of the exam and reduce the need for a second scope.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stopping GLP-1 receptor agonists (like semaglutide or tirzepatide) for one week before an upper endoscopy
What this could lead to: If a one-week pause improves stomach visibility, it could lead to a simple, safer pre-endoscopy guideline for people on these popular diabetes and weight-loss drugs.
What could go wrong: This is a small, single-center trial, so results may not apply broadly. Stopping GLP-1 drugs could cause blood sugar spikes or other side effects in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLP-1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLP-1

Contacts and locations

Locations

FJUH
RECRUITING

New Taipei City, Taiwan, 24352, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.